Key result
The SARS-CoV-2 B.1.427/B.1.429 variant reduced neutralizing antibody titers by 3-6 fold in plasma from mRNA-vaccinated and convalescent individuals compared to wildtype virus.
Population
Plasma from vaccinated or convalescent individuals and 35 RBD-specific mAbs
Design
In vitro neutralization assay
Authors
Loading...
May signal need for variant surveillance in vaccination; leaves open human clinical protection data.
Effect estimate: 3-6 fold reduction
The B.1.427/B.1.429 SARS-CoV-2 variant exhibits significant immune evasion from both vaccine-induced/convalescent plasma and specific monoclonal antibodies due to mutations in the spike protein.
McCallum et al. (2021) studied SARS-CoV-2 immunity (n=65). SARS-CoV-2 B.1.427/B.1.429 variant vs. Wildtype (D614G) SARS-CoV-2 was evaluated on Neutralizing antibody titers (GMT) against pseudoviruses (3-6 fold reduction). The SARS-CoV-2 B.1.427/B.1.429 variant reduced neutralizing antibody titers by 3-6 fold in plasma from mRNA-vaccinated and convalescent individuals compared to wildtype virus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: